





## Speaker

### Nuala Calnan, PhD CEO, BioPharm Excel

Founder, The Quality Risk Management Institute

Nuala is a 25 year veteran of the pharmaceutical industry. Her work as a consultant, academic, author and commentator is directed toward the development of practical, patient-focused excellence and has included research for FDA(USA), HPRA(Ireland) on enhancing patient safety and product quality in the manufacture and distribution of drugs.

Nuala works with organizations on transforming organizational culture, delivering more effective end-to-end risk management, implementing knowledge excellence strategies, behavior-based good data governance and enhancing performance management through people.

Nuala co-leads the ISPE Quality Culture Team and is a founding member of the ISPE/ PQLI Task Team on Knowledge Management. She is also the Arnold F. Graves Scholar with the Pharmaceutical Regulatory Science Team at TU Dublin, Ireland, where she leads a number of patient focused regulatory science research projects at Masters and PhD level.

Contact: <u>nuala.calnan@biopharmexcel.com</u> <u>nuala.calnan@theqrminstitute.com</u> LinkedIn: <u>https://www.linkedin.com/in/nuala-calnan-phd-a346067/</u>

**Connecting Pharmaceutical Knowledge** 

ISPE.org


Opening thoughts on

Learning and Unlearning!

# Preachers, Prosecutors, Politicians & Scientists!

"If you're a scientist by trade, rethinking is fundamental to your profession. You're paid to be constantly aware of the limits of your understanding. You're expected to doubt what you know, be curious about what you don't know, and update your views based on new data."

Grant, Adam. Think Again (pp. 19-20). Ebury Publishing. Kindle Edition.





Connecting Pharmaceutical Knowledge


4





























#### **Designing Measures for IMPACT** Table 4-A: An example of the IMPACT Tool for designing behavior-based LQIs Consistent delivery of high-quality medicinal products. IDENTIFY GOAL Organize team briefings on the consequences of rejected or delayed batch approvals for the business and the patient. Increase the number of RFT batches to X%. ACTIVATE THE Review outcomes from recent rejected or delayed batches or relevant customer complaints with the team. SELECT THE MEASURE 3. Senior leadership and local management celebrate/acknowledge each RFT batch during Gemba walks. 4. Use local visual management boards for motivation on progress toward goal. Promote and coach for enhanced attention to detail 1. 5. Acknowledge and recognize improvement efforts by team members in team/public through leadership and vision, as well as routine Gen areas/newsletters 2. Encourage a speak-up culture where concerns, issue PINPOINT THE BEHAVIORS 6 Motivate the team through team awards, e.g., movie tickets, team lunches. manner in a neutral, constructive forum. Learning teams use root cause analysis (RCA) tools to proactively identify and document solutions to issues raised. Begin proactive daily multidisciplinary interim batch it and resolution. 2. Lessons learned are documented and shared with wider workforce. 3. Lunch-and-learn sessions are arranged to facilitate Q&A between different improvement teams 4. Create improvement case studies in a shared area on intranet. I Ols/I Bk Leading 1. Measure and report attendance at the multidisciplinary daily meetings. 2. Number of employee/team RFT improvement suggestions implemented (by period). 3. Number of good catches identified at interim batch reviews (by batch). 4. Number of successful RCA exercises completed (by period). International Society for Pharmaceutical Engineering, "The Cultural Excellence Report – Six Key Dimensions", April 2017, available for download **Trended Lagging** at: https://www.ispe.org/products/cultural-excellence-% RFT batch approvals/investigation free lots. report-six-key-dimensions. 2. % RFT batch records (paperwork completions). ISPE. ISPE.org **Connecting Pharmaceutical Knowledge** 17

17





as PRECURSOR to BECOMING a HIGH-PERFORMANCE ORGANIZATION ...where the corporate culture is committed to the continuous and deliberate improvement of company performance AND the circumstances of those who work there—

and is a precursor to becoming a highperformance organization.

Paris Jr., Joseph F., State of Readiness: Operational Excellence as Precursor to Becoming a High-Performance Organization (p. 10). Greenleaf Book Group Press. Kindle Edition.

Thank You for your time today

## Thanks to the Team

The Team		
Name	Company	
Nuala Calnan	BioPharm Excel	
Erika Ballman	Perrigo	
Harry Jeffreys	Bausch Health	
Christine Teipen Smith	Eli Lilly	
T. David Hansen	J&J	
Jason Schneider	Abbvie	
Lorraine Thompson	Novartis	
Steve Alcorn	Novartis	
Brian Cutler	J&J	
Lewis Elliot	Novartis	
Matt Pearson	Genentech	